Phase I Clinical Study of N-[(4-Chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641)

J. D. Hainsworth, K. R. Hande, W. G. Satterlee, J. Kuttesch, D. H. Johnson, G. Grindey, J. E. Jackson, F. A. Greco

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Between February 1987 and July 1988, 45 patients with advanced refractory cancer were treated with LY186641, a diarylsulfonylnrea that has shown a broad spectrum of activity in preclinical testing. Patients received a weekly p.o. dose of LY186641 for 6 consecutive weeks; responding and stable patients continued weekly therapy until progression occurred. Using a standard phase I study design, the first three patients received LY186641 at 30 mg/m2 week; the dose was escalated in subsequent patients until dose-limiting toxicity occurred. Methemoglobinemia was the major toxicity observed and was dose related. Methemoglobin levels peaked approximately 24 h after LY186641 was administered and fell to low levels after 48 h. Six patients developed fatigue, cyanosis, and dyspnea associated with serum methemoglobinemia levels of >20%; four of these patients were subsequently removed from the study. Hemolytic anemia was also observed but was clinically significant in only 10 patients. Other side effects were mild and infrequent. The maximum tolerated dose of LY186641, when given at this schedule, was 2550 mg/m2/week. No objective tumor responses were observed.

Original languageEnglish (US)
Pages (from-to)5217-5220
Number of pages4
JournalCancer Research
Issue number18
StatePublished - Sep 15 1989

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase I Clinical Study of N-[(4-Chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641)'. Together they form a unique fingerprint.

Cite this